← Research library

Vladonix: clinical report on a tissue-derived preparation

Comparison in people · 2006

What was studied
76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.
Main finding
In the 76-person institute report, CD4-positive cells were 34.6% after adjunctive oral Vladonix and 30.8% after usual care, compared with a shared 28.5% baseline column.

Reported findings and study design

42 received adjunctive Vladonix and 34 conventional treatment alone. Peripheral-blood immunophenotyping used immunofluorescence. Immunoglobulins were measured by radial immunodiffusion.

Population or model 76 patients: 42 adjunctive Vladonix; 34 controls. Prior low-dose radiation exposure or radiation/chemotherapy.

Dose, route and schedule

One to three oral capsules, two to three times daily before meals for 15–20 days. The report lists 10 mg of thymus extract per capsule. Both arms received conventional care.

Protocol source ↗ · Russian institute-report reproductions, methods and Table 2

Results · Russian institute-report reproductions, methods and Table 2
MeasureResultComparison, timing and statistics
CD4-positive cells34.6% vs 30.8%Vladonix plus usual care versus usual care. Shared baseline 28.5%. · Vladonix value marked p < 0.05 versus baseline.
CD3-positive cells55.7% vs 51.9%Shared baseline 46.5%. · Vladonix value marked p < 0.05 versus baseline.
CD4/CD8 ratio1.4 vs 1.2Shared baseline 1.1. · Vladonix value marked p < 0.05 versus baseline.
IgM, IgG, IgA and CD8-positive cellsNo significant change markedTable 2 significance markers do not apply to these rows.

The report provides a shared baseline column and no clear between-arm test. Its biomarker results do not establish fewer infections or better cancer outcomes.

Source for these results ↗ · Reviewed 2026-11-13

Study limitations and source details

Study limitations

  • Sex counts differ between prose and table. Immune biomarkers do not establish protection from radiation, fewer infections or improved cancer outcomes.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Source details

Institute report — commercial reproduction

Russian institute-report reproductions, methods and Table 2

Sources checked

Citation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Human comparative studyRussian-language source

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution). Vladonix: clinical report on a tissue-derived preparation Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards